ESSEX BIO-TECH (01061) announces its interim performance: a net profit of HKD 163 million for the period, representing a year-on-year increase of 3.79%.
Yisheng Biological Technology (01061) announced its interim performance for the six months ending June 30, 2025, with a revenue of 8...
Essex Bio-Tech (01061) announced its interim performance for the six months ending June 30, 2025, with revenue of HK$877 million, a year-on-year increase of 5.79%; net profit for the period was HK$163 million, a year-on-year increase of 3.79%; basic earnings per share were 28.82 HK cents; it plans to pay a interim dividend of HK 7 cents per share.
Related Articles
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Guosen: RWA welcomes the era of strict supervision.
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Guosen: RWA welcomes the era of strict supervision.
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
